More Stories

Cardiology Pharmaceuticals July 31, 2026

Another Look at Attruby Reveals Bolstered Benefits July 31, 2026

As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.

Structural Heart July 30, 2026

Knowing When to Intervene in Mitral Regurgitation July 30, 2026

A common question in structural heart cardiology is “when do we know to intervene?” and recently released 25-year mitral regurgitation data might just have given us an answer.

Cardiology July 27, 2026

The Career Perceptions of Heart Failure Cardiology July 27, 2026

Picture this – you graduate medical school (not easy), you do a three-year internal medicine residency, then a three-year general cardiology fellowship, and another year of fellowship, but you’re paid less than your peers in other subspecialties – congrats, you’re an advanced heart failure cardiologist (AHFTC).

Cardiology Business July 23, 2026

The Cost of Cardiology is Driven by Insurers July 23, 2026

New price transparency data reveals how wildly insurance payments, reimbursements, and facility fees for cardiology swing across insurers and states, which underscores the complexity of U.S. healthcare costs.

Heart Failure July 22, 2026

How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 22, 2026

Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life.

Cardiology Pharmaceuticals July 20, 2026

An Oral PCSK9i and What it Means for Merck July 20, 2026

PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they’ve all required injection, and some even refrigeration. That just changed, however, with the FDA’s approval of Merck's Lipfendra (enlicitide), the first ever oral PCSK9i.

Get twice-weekly insights on the biggest stories shaping cardiology.